Ground Swell Capital LLC Invests $270,000 in GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Ground Swell Capital LLC has acquired a new stake in GSK PLC valued at approximately $270,000, adding 6,978 shares to its portfolio during the first quarter.
• GSK reported earnings of $1.23 per share for the recent quarter, surpassing estimates of $1.12, and generated revenue of $10.64 billion, significantly above expectations of $7.92 billion.
• The company recently declared a quarterly dividend of $0.4206, representing an annualized dividend yield of 4.3%, with a payout ratio of 79.17%.

Ground Swell Capital LLC purchased a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,978 shares of the pharmaceutical company's stock, valued at approximately $270,000.

A number of other institutional investors also recently modified their holdings of GSK. HHM Wealth Advisors LLC raised its holdings in GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares in the last quarter. Costello Asset Management INC bought a new stake in GSK during the first quarter worth about $31,000. Richardson Financial Services Inc. raised its holdings in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC bought a new stake in GSK during the first quarter worth about $36,000. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in GSK by 525.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on GSK shares. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $37.38.

GSK Stock Performance

Shares of GSK stock traded up $0.07 during trading on Friday, reaching $39.30. 3,038,539 shares of the company's stock were exchanged, compared to its average volume of 4,741,255. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $80.14 billion, a PE ratio of 18.19, a PEG ratio of 1.71 and a beta of 0.51. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The firm's fifty day moving average price is $38.50 and its 200-day moving average price is $37.97.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%. The firm's revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.43 EPS. As a group, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.3%. GSK's dividend payout ratio (DPR) is 79.17%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.